

PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/693538-Conf. #4018
				Filing Date	October 23, 2003
				First Named Inventor	Michele SANICOLA-NADEL
				Art Unit	1643
				Examiner Name	P. K. Tungaturthi
Sheet	1	of	2	Attorney Docket Number	BGNA117CN

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PKT	A1*	US-5,256,643	10-26-1993	Persico et al.	
	A2*	US-5,264,557	11-23-1993	Salomon et al.	
	A3*	US-5,654,140	08-05-1997	Persico et al.	
	A4*	US-5,792,616	08-11-1998	Persico et al.	
	A5*	US-20040176576-A1	09-09-2004	McKenzie et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
PKT	B1	WO-00/06723-A1	02-10-2000	Yeda Research and Development Company Ltd. at the Weizmann Institute of Science		
	B2	WO-00/63693-A1	10-26-2000	Kokolus, William, J.		
	B3	WO-02/22808-A2	03-21-2002	Biogen, Inc.		
	B4	WO-02/059620-A2	08-01-2002	The Government of the United States of America		
	B5	WO-02/077033-A1	10-03-2002	The Austin Research Institute		
	B6	WO-03/083041-A2	10-09-2003	Sanicola-Nadel, Michele, et al.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PKT	C1	Bianco, Caterina, et al., "Cripto-1 Indirectly Stimulates the Tyrosine Phosphorylation of erb B-4 through a Novel Receptor," <i>The Journal of Biological Chemistry</i> , Vol. 274(13):8624-8629 (1999)	
	C2	Brandt, Ralf, et al., "Identification and Biological Characterization of an Epidermal Growth Factor-related Protein: Cripto-1," <i>The Journal of Biological Chemistry</i> , Vol. 269(25):17320-17328 (1994)	
	C3	Clardiello, Fortunato, et al., "Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides," <i>Oncogene</i> , Vol. 9:291-298 (1994)	
	C4	Ciccociola, Alfredo, et al., "Molecular characterization of a gene of the 'EGF family' expressed in undifferentiated human NTERA2 teratocarcinoma cells," <i>The EMBO Journal</i> , Vol. 8(7):1987-1991 (1989)	
	C5	Dublin, Edwin A., et al., "Amphiregulin and cripto overexpression in breast cancer: relationship with prognosis and clinical and molecular variables," <i>International Journal of Oncology</i> , Vol.	
Examiner Signature	/Parithosh K Tungaturthi/		Date Considered 10/26/2006


Substitute for form 1448A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete If Known</b>		
			Application Number	10/693538-Conf. #4018	
			Filing Date	October 23, 2003	
			First Named Inventor	Michele SANICOLA-NADEL	
			Art Unit	1643	
			Examiner Name	P. K. Tungaturthi	
			Attorney Docket Number	BGNA117CN	
Sheet	2	of	2		

		7:617-622 (1995)	
PXT	C6	Ebert, Andreas D., et al., "Cripto-1 Induces Phosphatidylinositol 3'-Kinase-dependent Phosphorylation of AKT and Glycogen Synthase Kinase 3 $\beta$ in Human Cervical Carcinoma Cells," <i>Cancer Research</i> , Vol. 59:4502-4505 (1999)	
	C7	Kannan, Subha, et al., "Cripto Enhances the Tyrosine Phosphorylation and Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells," <i>The Journal of Biological Chemistry</i> , Vol. 272(6):3330-3335 (1997)	
	C8	Normanno, Nicola, et al., "Expression of amphiregulin, cripto-1, and heregulin $\alpha$ in human breast cancer cells," <i>International Journal of Oncology</i> , Vol. 2:903-911 (1993)	
	C9	Saeki, Toshiaki, et al., "Expression of cripto-1 in human colorectal adenomas and carcinomas is related to the degree of dysplasia," <i>International Journal of Oncology</i> , Vol. 5:445-451 (1994)	
	C10	Saeki, Toshiaki, et al., "Immunohistochemical detection of cripto-1, amphiregulin and transforming growth factor alpha in human gastric carcinomas and intestinal metaplasias," <i>International Journal of Oncology</i> , Vol. 5:215-223 (1994)	
	C11	Salomon, D.S., et al., "The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer," <i>Endocrine-Related Cancer</i> , Vol. 7:199-226 (2000)	
	C12	International Search Report Application No. PCT/US02/11950, dated September 5, 2003	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Parithosh K Tungaturthi/	Date Considered	10/26/2006
--------------------	---------------------------	-----------------	------------



PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			<b>Complete If Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/693538-Conf. #4018	
			Filing Date	October 23, 2003	
			First Named Inventor	Michele SANICOLA-NADEL	
			Art Unit	1643	
			Examiner Name	P. K. Tungaturthi	
Sheet	1	of	2	Attorney Docket Number	BGNA117CN

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
PKT	A1*	US-5,256,643	10-26-1993	Persico et al.	
	A2*	US-5,264,557	11-23-1993	Salomon et al.	
	A3*	US-5,654,140	08-05-1997	Persico et al.	
	A4*	US-5,792,616	08-11-1998	Persico et al.	
	A5*	US-20040176576-A1	09-09-2004	McKenzie et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
PKT f	B1	WO-00/06723-A1	02-10-2000	Yeda Research and Development Company Ltd. at the Weizmann Institute of Science		
	B2	WO-00/63693-A1	10-26-2000	Kokolus, William, J.		
	B3	WO-02/22808-A2	03-21-2002	Biogen, Inc.		
	B4	WO-02/059620-A2	08-01-2002	The Government of the United States of America		
	B5	WO-02/077033-A1	10-03-2002	The Austin Research Institute		
	B6	WO-03/083041-A2	10-09-2003	Sanicola-Nadel, Michele, et al.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
PKT	C1	Bianco, Caterina, et al., "Cripto-1 Indirectly Stimulates the Tyrosine Phosphorylation of erb B-4 through a Novel Receptor," <i>The Journal of Biological Chemistry</i> , Vol. 274(13):8624-8629 (1999)			
	C2	Brandt, Ralf, et al., "Identification and Biological Characterization of an Epidermal Growth Factor-related Protein: Cripto-1," <i>The Journal of Biological Chemistry</i> , Vol. 269(25):17320-17328 (1994)			
	C3	Ciardiello, Fortunato, et al., "Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides," <i>Oncogene</i> , Vol. 9:291-298 (1994)			
	C4	Ciccocioppa, Alfredo, et al., "Molecular characterization of a gene of the 'EGF family' expressed in undifferentiated human NTERA2 teratocarcinoma cells," <i>The EMBO Journal</i> , Vol. 8(7):1987-1991 (1989)			
	C5	Dublin, Edwin A., et al., "Amphiregulin and cripto overexpression in breast cancer: relationship with prognosis and clinical and molecular variables," <i>International Journal of Oncology</i> , Vol.			
Examiner Signature				Date Considered	1/15/06


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/693538-Conf. #4018
				Filing Date	October 23, 2003
				First Named Inventor	Michele SANICOLA-NADEL
				Art Unit	1643
				Examiner Name	P. K. Tungaturthi
Sheet	2	of	2	Attorney Docket Number	BGNA117CN

PCT	7:617-622 (1995)	
C6	Ebert, Andreas D., et al., "Cripto-1 Induces Phosphatidylinositol 3'-Kinase-dependent Phosphorylation of AKT and Glycogen Synthase Kinase 3 $\beta$ in Human Cervical Carcinoma Cells," <i>Cancer Research</i> , Vol. 59:4502-4505 (1999)	
C7	Kannan, Subha, et al., "Cripto Enhances the Tyrosine Phosphorylation and Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells," <i>The Journal of Biological Chemistry</i> , Vol. 272(6):3330-3335 (1997)	
C8	Normanno, Nicola, et al., "Expression of amphiregulin, cripto-1, and heregulin $\alpha$ in human breast cancer cells," <i>International Journal of Oncology</i> , Vol. 2:903-911 (1993)	
C9	Saeki, Toshiaki, et al., "Expression of cripto-1 in human colorectal adenomas and carcinomas is related to the degree of dysplasia," <i>International Journal of Oncology</i> , Vol. 5:445-451 (1994)	
C10	Saeki, Toshiaki, et al., "Immunohistochemical detection of cripto-1, amphiregulin and transforming growth factor alpha in human gastric carcinomas and intestinal metaplasias," <i>International Journal of Oncology</i> , Vol. 5:215-223 (1994)	
C11	Salomon, D.S., et al., "The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer," <i>Endocrine-Related Cancer</i> , Vol. 7:199-226 (2000)	
C12	International Search Report Application No. PCT/US02/11950, dated September 5, 2003	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	1/15/06
--------------------	---	-----------------	---------